Overview

Korean Post-marketing Surveillance for Reyataz®

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Reyataz® so that the regulatory authority can manage the marketing approval properly
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Atazanavir Sulfate